ReviewContraception and reproductive medicine2025
Management of abnormal bleeding in etonogestrel-releasing implant users: quo vadis? An exploratory study on the attitudes of a cohort of Italian gynaecologists and review of the literature.
Review in Contraception and reproductive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLong-acting reversible contraceptives (LARCs) are increasingly gaining popularity due to their high efficacy and ease of use compared to short-acting reversible contraceptives (SARCs). Among available LARCs, the etonogestrel (ENG) subdermal implant represents a particularly effective contraceptive method. However, many patients request early removal of the device due to the persistence of unfavourable bleeding patterns.
methodsWe developed a short, multiple-choice ad hoc questionnaire distributed online from October 2024 to March 2025 to investigate the attitude of Italian gynaecologists towards medical treatment of unfavourable bleeding in women using the ENG-releasing implant. A total of 141 physicians responded reporting their first- and second-line treatments for patients with and without a contraindication to combined oral contraceptives (COC). We discuss the results of our survey in the light of the existing literature, through a systematic review including studies evaluating medical treatments in ENG implant users experiencing troublesome bleeding. RESULTS AND
conclusionThe results of our survey and the review of the literature highlight the diverse, sparse, and sometimes confused approaches to unfavourable bleeding in ENG implant users. In our survey, up to 19% of practitioners indicated they would not know what to do in different case scenarios. In order to help gynaecologists gain greater confidence in managing this symptom, large randomised controlled trials (RCTs) with long-term follow-up on which clinical guidelines and standardized training programs can be based, are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.